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RESULTS: Patients (n=660, 100% completion rate) completed the survey. All 
attributes were significant predictors of choice except sleepiness. Respondents 
were significantly more likely to choose a treatment that provided a 10% 
reduction in seizure frequency (Odds Ratio [OR]=1.75, 95% CI 1.68-1.82) or avoided 
weight gain (3lb) (OR=0.751, 95% CI=0.731-0.772). Respondents were willing to pay 
an additional £39 and £20 per month for AEDs with those attributes. 
Furthermore, respondents who become unresponsive during a seizure placed 
higher levels of preference on an AED that would reduce seizure frequency. 
Respondents who reported higher levels of adherence to their AEDs (MMAS-8) 
reported better quality of life (QoL) (QOLIE-31-P and EQ-5D-5L). CONCLUSIONS: 
Seizure reduction is the most important AED attribute to epilepsy patients, but 
lack of weight gain is also valued. Higher adherence to AEDs appears to be linked 
with improved QoL.  
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OBJECTIVES: Disease modifying therapies (DMTs) decrease relapses in patients 
with multiple sclerosis (MS). Due to their wide variety of risk/benefit attributes, 
patients must weigh their preferences when choosing DMTs. We determine 
patient preferences for DMTs risk/benefit attributes. METHODS: Our choice-
based conjoint (CBC) survey developed using Sawtooth software was given in-
person, to 300 consenting adults with relapsing remitting MS at University of 
California, San Francisco’s MS clinic. Each patient answered 16 choice tasks. 
They chose one of two choices with 3-4 different levels of 6 risk and benefit 
attributes of hypothetical DMTs. Benefits included delayed progression, reduced 
relapses, and symptom improvement. Risks were mild side effects (SEs), serious 
SEs, and administration route and frequency. Analysis used mixed-effects 
logistic regression. RESULTS: Patients were 76% female; 75% with mild, 18% 
moderate, and 7% severe disease. All 6 attributes significantly impacted patient 
preference. Of the benefits, the preferences were highest for preventing 
progression 10 vs 2 years (odds ratio [OR]=2.27, p<0.001) and for substantial vs no 
improvement in symptoms (OR=3.67, p<0.001). Patients may be willing to accept 
a 0.05-0.1% risk of serious SEs leading to death (OR=0.57-0.66; p<0.001) to gain a 
moderate to substantial benefit from their therapy. A 1% risk of serious SE 
compared to no risk (OR=0.22, p<0.001) resulted in very low preference, but had a 
comparable magnitude in preference to a substantial improvement in symptoms 
vs no improvement (OR=1.60, p<0.001). Compared to daily subcutaneous 
administration, patients preferred daily oral administration (OR=2.15, p<0.001), 
then monthly intravenous (OR=1.54, p<0.001), and then intramuscular weekly 
(OR=1.19, p<0.01). CONCLUSIONS: Patients are willing to make risk/benefit 
tradeoffs in medication selection. Patient prefer treatments that delay 
progression or improve symptoms to those that prevent relapses (the primary 
outcomes of many clinical trials). Oral and monthly administration is preferred.  
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INSOMNIA - AS COMORBIDITY OF INCONTINENCE AND OVERACTIVE BLADDER 
- IMPACTS HEALTH STATUS, EVERYDAY FUNCTIONING AND WORK DISABILTY  
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OBJECTIVES: Insomnia - defined as a difficulty in initiating or maintaining sleep 
– is known to accompany chronic diseases as comorbidity. Nevertheless, the 
impact of insomnia - as a comorbidity of overactive bladder and incontinence- 
on overall burden of illness is unclear. The objective of our study was thus to 
analyze the impact of insomnia as comorbidity of urological diseases on burden 
of illness of over a five year period. METHODS: In 2007, two representative adult 
samples of the Kantar Health European Healthcare Panel in Germany and UK 
were surveyed (n=72.605) and self-reports about insomnia, overactive bladder 
and incontinence were collected. In 2012, a subsample of 4.008 individuals was 
re-contacted and participants completed a general health, functional status  
and work disability questionnaire. RESULTS: In 2007, 3.2% of the initial 
representative sample reported overactive bladder, and 6.9% incontinence. A 
total of 38.9% of the individuals with one or both of these problems also suffered 
from insomnia. Five years later, in 2012, 26.1% of the entire group of individuals 
with one or both of the urological diseases indicated very good or excellent 
health, 45.9% experienced functional limitations and 28.1% suffered from work 
disability. In the subgroup of individuals with urological diseases in combination 
with insomnia, the percentage of individuals with very good/excellent health 
dropped to 15.2%, functional limitations increased to 61%, and 41.7% persons 
were disabled at their workplace. CONCLUSIONS: As these results demonstrate, 
insomnia is an important comorbidity of urological diseases and intensifies 
related burden of illness and reduces work related performance. Insomnia 
should be considered for inclusion into appropriate treatment strategies for 
urological diseases.  
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OBJECTIVES: To review disease- and condition-specific QoL instruments and 
their psychometric properties in Parkinson’s disease (PD), treatment options, and 
caregiver burden (CB). METHODS: A systematic literature search was conducted 
among peer-reviewed journals from January 2008 to December 2012 on quality of 
life (QoL) of PD patients or patients undergoing drug therapy in electronic 
databases such as Pubmed, PsycINFO, CINAHL, and Cochrane. A full review was 
conducted on articles that met the inclusion criteria. The search was limited to 
English language, full text availability, humans, and within five years; however, 
no time-frame was stipulated for CB. Meta-analyses, systematic reviews, or 
studies conducted exclusively outside the United States were excluded. For 
studies assessing CB, instruments not validated in PD population were excluded. 
RESULTS: The review identified seven disease-specific and two generic 
instruments assessing QoL in PD, 13 instruments recommended by the 
Movement Disorder Society in assessing QoL in patients undergoing drug 
therapy, and 12 instruments that assessed CB. A description of the domains, 
scaling, and psychometric properties of the instruments were included. 
Instruments ranged from comprehensive scales assessing all aspects of PD to 
recently developed instruments designed to assess a specific component of PD 
such as “wearing off” periods or freezing of gait. In PD patients undergoing drug 
therapy, four studies were identified that assessed patients in early PD and two 
studies focused on levodopa-induced motor fluctuations. Common domains 
assessed by the CB instruments were clinical, socio-demographic, emotional, 
and functional factors. Overall, Unified Parkinson’s Disease Rating Scale and 
Zarit Caregiver Burden Inventory were the most widely used instruments. 
CONCLUSIONS: Multiple factors contribute to the QoL in PD patients and their 
caregivers including disease severity, unpredictable disease progression, and 
adverse effects of treatment. This review highlights the instruments and their 
properties in PD and serves as a useful resource for researchers and clinicians.  
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OBJECTIVES: Using data from the Medical Expenditure Panel Survey (MEPS), we 
assessed quality-of-life (QoL) scores associated with insomnia and hypnotic use. 
METHODS: Dependent variables were the mental component summary (MCS) 
and physical component summary (PCS) scores from the 12-item Short-Form 
Health Survey (SF-12). These summary scores are standardized to 1998 
population norms (mean = 50; SD = 10). Multivariate regression analyses were 
used to compare cohorts while controlling for demographic and clinical 
characteristics. RESULTS: Of 104,274 adults in MEPS from 2005 through 2009, 
about 1.4% (n = 1,401) had a diagnosis of insomnia. Among those with a 
diagnosis, 45.6% (n = 639) used a prescription hypnotic. The mean PCS scores 
were 9.2 points lower for subjects with insomnia than without insomnia (PCS: 
40.6 ± SE0.5; PCS: 49.8 ± SE0.1, p < 0.001), while the mean MCS scores were 6.9 
points lower between the two groups (MCS: 44.1 ± SE0.1, MCS = 51.0 + SE0.1; p < 
0.001). After controlling for demographic and clinical characteristics, the 
difference remained significant (PCS: 5.1 points lower; MCS: 6.2 points lower; 
p<0.001). There was no difference in mean scores for insomnia patients who 
used hypnotics (n = 639; PCS: 40.6 ± SE0.8; MCS: 44.3 ± SE0.6) compared to those 
not using hypnotics (n = 762; PCS: 40.6 ± SE0.7, MCS: 43.9 ± SE0.5). 
CONCLUSIONS: Although patients with a diagnosis for insomnia had 
significantly lower physical and psychological QoL summary scores compared to 
those without this diagnosis, differences were not seen for those with a 
diagnosis and a prescription hypnotic compared to those with a diagnosis and no 
prescription hypnotic. Regression was used to control for differences in cohorts, 
but selection bias may still be a concern. Using a ‘before and after therapy’ 
design, with patients serving as their own controls is an important next step.  
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OBJECTIVES: Multiple sclerosis (MS) burdens not only the patients but also their 
caregivers. Caregivers have been described as “hidden patients” and they often 
experience social, psychological, emotional, and economic hardships. The study 
goal is to provide a comprehensive review of the instruments along with their 
psychometric properties that measure caregiver burden in MS. METHODS: A 
systematic literature search was conducted among peer-reviewed journals from 
2002-2012 in the databases PubMed, Cochrane Review, PsycINFO, and Medline to 
identify instruments that measured caregiver burden in MS. In addition, the 
review also evaluated the instrument’s psychometric properties such as 
reliability and validity. Clinical and review studies were excluded from the 
review. RESULTS: A total of nine caregiver burden instruments were identified 
that were utilized in MS population. The instruments varied widely with respect 
to items and domains, administration, scaling and scoring. The number of items 
and domains in the instruments ranged from 1-7 and 9-29, respectively. All the 
instruments displayed adequate psychometric properties. The Zarit Burden 
Interview scale has been extensively used to measure caregiver burden in MS in 
numerous countries. The scale measures the domains of health, psychology, 
finance and social, and adequately gauges the possible facets that MS caregivers 
typically experience. The scale is reliable and valid with an internal consistency 
ranging between 0.70 and 0.93, test re-test reliability of 0.71, and an intra-class 
correlation of 0.89. CONCLUSIONS: The importance of measuring caregiver 
burden in MS has been recognized and researched in several countries. 
Interestingly, there is a dearth of studies conducted in the United States. 
Caregiver burden in MS should be assessed due to the multi-dimensional threat 
it imposes on caregivers. The assessment of caregiver burden can assist 
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providers in better understanding the needs of the caregivers, thereby, ensuring 
optimal outcomes for their patient.  
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PATIENTS WITH STROKE IN INDIA  
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OBJECTIVES: To assess the impact of stroke on patient’s health related quality of 
life (HRQOL) using EQ-5D. METHODS: A convenient sample of 300 patients were 
recruited from six medical centers across three cities (Mumbai, Bangalore, and 
Delhi) in India. Patients older than 18 years diagnosed with stroke between June 
2011 to June 2012 who were receiving therapy for stroke were included in the 
study. Data on patients' socio-demographics, diagnosis, relevant clinical 
complications, were collected using a paper-based case report form. Patients 
were asked to rate their overall health using the EQ-VAS scale and data on the 
five dimensions of quality of life was collected using the EQ-5D questionnaire 
that was administered by trained interviewers. Translated and validated 
versions of the EQ-5D and EQ-VAS scales for five Indian languages were used in 
the study. RESULTS: The mean age of patients in the study was 58 (SD 14.45) and 
majority (70%) of the patients were males. Of the 300 patients, 60% had ischemic 
stroke. The mean EQ-VAS score was 66 (SD 23.09). Age and socioeconomic status 
were significant predictors (p<0.05, p<0.001 respectively) of EQ-VAS score. 
However, these variables were negatively correlated with the EQ-VAS score 
indicating that patients who were older and from an upper socioeconomic strata 
rated their overall health to be lower. Additionally, the frequency of problems 
was higher among older patients on mobility and usual care domains of the EQ-
5D scale than younger patients. CONCLUSIONS: These findings suggest the value 
of measuring health status among stroke patients in addition to assessing 




IMPACT OF VELAGLUCERASE ALFA ON QUALITY OF LIFE OF ADULT PATIENTS 
WITH TYPE-I GAUCHER DISEASE  
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OBJECTIVES: Type-1 Gaucher Disease (GD1) causes anemia, thrombocytopenia, 
hepatosplenomegaly, and skeletal pathology. Patients’ health-related quality of 
life (HRQoL) has been shown to be significantly diminished relative to the U.S. 
general population. Velaglucerase alfa is an enzyme replacement therapy (ERT) 
with the most comprehensive clinical trial registration program for an approved 
ERT in GD1 and has been reported as an effective and well-tolerated therapy. 
METHODS: The change in HRQoL, measured using the Short-Form-36 version 2 
(SF-36 v2) in adults at baseline and 1 year in a randomized, double-blinded, 
parallel-group, two-dose Phase III clinical trial of velaglucerase alfa, was 
designated a priori a non-key secondary endpoint. RESULTS: The mean baseline 
(SD) was 42.3 (8.00) and 46.0 (5.90) for the norm-based Physical Component 
Summary (PCS) and 41.7 (12.6) and 48.1 (10.7) for the norm-based Mental 
Component Summary (MCS), respectively, for the 45 U/kg (N=8) and 60 U/kg 
(N=7) treatment arms; the mean U.S. normal population score=50; 1 SD=10). 
Fourteen adult GD1 patients had completed both a baseline and 1 year SF-36 
HRQoL assessment (N=8 receiving 45 U/kg; N=6 receiving 60 U/kg). The respective 
mean change at 1 year [95% CI] for the PCS and MCS was 4.2 [-4.6, 13.0] and 4.1 
[1.0, 7.2] at the low dose and 1.7 [-3.9, 7.2] and 1.2 [-7.9, 10.3] at the high dose. 
Non-significant increases were observed in nearly all of the 8 individual SF-36 v2 
health domains compared to baseline, however, the mean increases, as well as 
the mean increases in the norm-based PCS and MCS summary measures, were 
aligned with the expected achievements of therapeutic goals for HRQoL. 
CONCLUSIONS: In addition to clinical efficacy and safety, velaglucerase alfa 
showed clinically important increases in HRQoL in adults as measured by the SF-
36 v2 within 1 year, however, further studies are needed.  
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OBJECTIVES: Orphan drugs are therapies for low prevalence or neglected 
diseases with high unmet need. Many drugs have received orphan status 
globally, and benefited from 5-10 year marketing exclusivity; reduced 
stakeholder evidence requirements with unmet need weighing heavily into 
health technology assessment (HTA) and reimbursement decision-making; and 
largely uncontested pricing. Given tightening health system budgets, the 
proliferation of high priced orphan drugs in the United States (US) and Europe 
(EU) have caused these therapies to come under increased scrutiny from HTA 
agencies and payers to demonstrate value. To gain insight into evolving market 
access requirements, we conducted a multimarket review of orphan drug HTAs 
and reimbursement decisions comparing them to top selling non-orphan drugs 
in the US and EU. METHODS: Global HTAs and coverage decisions for orphan and 
blockbuster drugs were characterized and compared based on health economic, 
clinical and other value-based requirements. An analysis of orphan drug pricing 
was also conducted where pricing was available. RESULTS: More than 20 orphan 
drug HTAs were identified, including those for genetic and central nervous 
system disorders, cancer and cardiovascular disease. HTA agencies and payers 
scrutinized the robustness of clinical evidence and lack of comparator data. 
Cost-effectiveness was also often evaluated, though with relaxed ICER 
thresholds compared to non-orphan drugs. Failure of an orphan drug to meet 
historically accepted evidentiary thresholds have led some evaluators to grant 
conditional reimbursement, with the proviso that further supportive evidence 
must be provided, although outright reimbursement denial has become 
increasingly common. CONCLUSIONS: Once considered “reimbursement-safe” 
for drug developers, to achieve unrestricted reimbursement from payers orphan 
drugs now face higher evidentiary hurdles that are increasingly similar to non-
orphan drugs. New pharmaceuticals intent on achieving optimal market access 
as an orphan drug must factor the evolving requirements for demonstrating 
value into clinical and health economic evidence generation plans.  
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COMPARING ADHERENCE RATES TO DISEASE MODIFYING THERAPIES FOR 
MULTIPLE SCLEROSIS IN COMMERCIAL ENROLLEES AND PART D 
BENEFICIARIES  
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OBJECTIVES: To compare adherence rates, defined as the Medication Possession 
Ratio (MPR), for patients using alternative disease modifying therapies (DMTs)  
to treat multiple sclerosis (MS) that are enrolled in either a commercial 
insurance plan or through the Part D Medicare beneficiary program. METHODS: 
Study patients had >1 pharmacy DMT claim [interferon, glatiramer acetate (GA), 
fingolimod or natalizumab] and were enrolled in either a commercial health  
plan or Part D program between the dates of January 2010 and October 2012  
for patients using interferon, GA and natalizumab and between the dates of 
October 2010 and October 2012 for patients using fingolimod. Mean monthly MPR 
rates were calculated as the percentage of time the patient had access to a 
specific medication. RESULTS: The MPR for 243,330 and 197,784 commercial and 
Part D beneficiaries, respectively, were calculated across the study period. 
Adherence rates for commercial enrollees were similar across disease modifying 
therapies ranging from 75.4% for a once daily oral therapy to 79% for 
natalizumab. However, adherence in Medicare Part D beneficiaries was 
consistently lower than patients enrolled in commercial plans ranging from a 
reduction in MPR of 0.27% for GA to 7.4% in patients taking once daily oral 
fingolimod treatment. CONCLUSIONS: Medicare Part D beneficiaries had lower 
rates of adherence compared to MS patient enrolled in commercial plans which 
could present a unique opportunity for medication management programs 




EFFECT OF NEUROLOGIST AMBULATORY VISITS ON USE OF DISEASE-SPECIFIC 
PHARMACOTHERAPIES FOR CHRONIC NEUROLOGICAL CONDITIONS  
Ney JP1, Watanabe JH2, van der Goes DN3 
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OBJECTIVES: Neurologists care for chronic neurological illnesses through the use 
of disease-specific pharmacotherapies, but any licensed medical provider can 
prescribe these medications. Therefore, we evaluate effect of neurologist care on 
usage of disease-specific pharmacotherapies for chronic neurological diseases. 
METHODS: Survey respondents from the 2002-2010 Medical Expenditure Panel 
Survey(MEPS), an annual representative dataset of the civilian non-
institutionalized US population, were identified for multiple sclerosis, 
parkinsonism, epilepsy, and dementia. Data collection included prescription 
classes and sub classes (from Cerner Multum) for determining immuno-
modulatory, antiparkinsonian, anticonvulsant, and antidementia medications, 
identified neurologist ambulatory visits, age, illness duration, race, income, 
gender, education, comorbidities, region and year of care. Survey-weighted 
multivariate logistic and ordinary least squares regressions were performed on 
the outcomes of disease specific prescriptions and costs for the calendar year. 
Subgroup analyses were performed for each index condition. RESULTS: A total of 
4948 MEPS respondents (weighted sample: 5.1 million US citizens, 95% CI 4.8m-
5.4m) reported one or more index conditions. Only 27% reported a neurologist 
ambulatory care visit. Neurologist visits were associated with illness duration, 
high school graduate education, insurance coverage, and income. For the group 
seeing a neurologist, the adjusted likelihood of a patient with one of the four 
identified chronic neurological diseases receiving a disease-specific medication 
was substantially greater (OR 2.7, p-value <0.001) and adjusted annual 
expenditures for these medications was a mean of $1780 more (p-value <0.001); 
these estimates varied but were significant for all disease subgroups. 
CONCLUSIONS: Patients are much more likely to receive disease-specific 
pharmacotherapies for chronic neurological conditions when a neurologist is 
involved with their care. Policy makers and pharmaceutical companies should 
consider specialist physician involvement in care as a factor in determining the 
impact of new disease-specific medications.  
 
PND47  
HOW CAN WE USE DISCRETE EVENT SIMULATION TO IMPROVE ACCESS TO 
HEALTH CARE: AN ASSESSMENT OF INCREASING ACCESS TO CARE FOR 
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